These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34473298)

  • 1. Telomerase as a therapeutic target in glioblastoma.
    Aquilanti E; Kageler L; Wen PY; Meyerson M
    Neuro Oncol; 2021 Dec; 23(12):2004-2013. PubMed ID: 34473298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
    Aquilanti E; Kageler L; Watson J; Baird DM; Jones RE; Hodges M; Szegletes ZM; Doench JG; Strathdee CA; Figueroa JRMF; Ligon KL; Beck M; Wen PY; Meyerson M
    Neuro Oncol; 2023 Jul; 25(7):1275-1285. PubMed ID: 36694348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
    Bollam SR; Berens ME; Dhruv HD
    Curr Neurol Neurosci Rep; 2018 Mar; 18(4):15. PubMed ID: 29525892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
    Mancini A; Xavier-Magalhães A; Woods WS; Nguyen KT; Amen AM; Hayes JL; Fellmann C; Gapinske M; McKinney AM; Hong C; Jones LE; Walsh KM; Bell RJA; Doudna JA; Costa BM; Song JS; Perez-Pinera P; Costello JF
    Cancer Cell; 2018 Sep; 34(3):513-528.e8. PubMed ID: 30205050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-specific loss of
    Amen AM; Fellmann C; Soczek KM; Ren SM; Lew RJ; Knott GJ; Park JE; McKinney AM; Mancini A; Doudna JA; Costello JF
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33758097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
    Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
    Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
    Fan X; Wang Y; Liu Y; Liu X; Zhang C; Wang L; Li S; Ma J; Jiang T
    J Neurooncol; 2016 Jul; 128(3):455-62. PubMed ID: 27230769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review.
    Pennisi G; Bruzzaniti P; Burattini B; Piaser Guerrato G; Della Pepa GM; Sturiale CL; Lapolla P; Familiari P; La Pira B; D'Andrea G; Olivi A; D'Alessandris QG; Montano N
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer.
    McKinney AM; Mathur R; Stevers NO; Molinaro AM; Chang SM; Phillips JJ; Costello JF
    Cell Rep; 2022 Sep; 40(12):111344. PubMed ID: 36130485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
    Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
    Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C; Wang Q; Yan X; Wang J
    Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
    Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations in cancer development.
    Heidenreich B; Rachakonda PS; Hemminki K; Kumar R
    Curr Opin Genet Dev; 2014 Feb; 24():30-7. PubMed ID: 24657534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes.
    Kessler T; Berberich A; Sadik A; Sahm F; Gorlia T; Meisner C; Hoffmann DC; Wick A; Kickingereder P; Rübmann P; Bendszus M; Opitz C; Weller M; van den Bent M; Stupp R; Winkler F; Brandes A; von Deimling A; Platten M; Wick W
    Cancer Med; 2020 Nov; 9(22):8373-8385. PubMed ID: 32991787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
    Yuan X; Larsson C; Xu D
    Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of TERT mutation in brain tumor cell lines.
    Johanns TM; Fu Y; Kobayashi DK; Mei Y; Dunn IF; Mao DD; Kim AH; Dunn GP
    Brain Tumor Pathol; 2016 Jul; 33(3):222-7. PubMed ID: 26960334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.